Published in PLoS One on February 28, 2012
A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (1997) 10.14
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol (2001) 4.55
The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev (2003) 4.47
The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 4.42
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene (2002) 2.66
New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene (2010) 2.56
Shedding light on ADAM metalloproteinases. Trends Biochem Sci (2005) 2.41
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A (2001) 2.27
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood (2004) 1.78
TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials (2009) 1.73
Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol (2007) 1.69
Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res (2010) 1.64
Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res (2003) 1.58
Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie (2007) 1.49
Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res (2007) 1.48
Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene (2003) 1.40
TRAILing death in cancer. Mol Aspects Med (2009) 1.36
Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood (2002) 1.31
Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol (2008) 1.09
Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. Clin Cancer Res (2008) 0.96
TRAIL-receptor antibodies as a potential cancer treatment. Future Oncol (2007) 0.92
Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Clin Cancer Res (2007) 0.90
Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Arch Immunol Ther Exp (Warsz) (2008) 0.90
Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1. Expert Opin Investig Drugs (2009) 0.86
Regulatory functions of TRAIL in hematopoietic progenitors: human umbilical cord blood and murine bone marrow transplantation. Leukemia (2010) 0.83
Caspase-8-dependent HER-2 cleavage in response to tumor necrosis factor alpha stimulation is counteracted by nuclear factor kappaB through c-FLIP-L expression. Cancer Res (2004) 0.83
Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. Int J Hematol (2008) 0.81
Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene (2003) 3.53
Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet (2006) 2.15
Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology (2003) 2.10
Retracted The chromatin-remodeling complex WINAC targets a nuclear receptor to promoters and is impaired in Williams syndrome. Cell (2003) 1.88
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood (2005) 1.85
Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med (2002) 1.84
Role of Ras signaling in the induction of snail by transforming growth factor-beta. J Biol Chem (2008) 1.83
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood (2004) 1.78
Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res (2009) 1.59
Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Cardiovasc Res (2005) 1.55
Clarithromycin-induced eosinophilic pneumonia. Intern Med (2004) 1.52
Clinical characteristics of bacteremia caused by Helicobacter cinaedi and time required for blood cultures to become positive. J Clin Microbiol (2014) 1.48
Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res (2007) 1.48
Whole-genome analyses reveal genetic instability of Acetobacter pasteurianus. Nucleic Acids Res (2009) 1.41
Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta. Endocrinology (2002) 1.40
Dermatomyositis with peripheral nervous system involvement: activation of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) in vasculitic lesions. Intern Med (2003) 1.40
Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma. Acta Haematol (2015) 1.38
Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res (2003) 1.32
Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation (2004) 1.32
Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood (2002) 1.31
High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation (2004) 1.27
Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest. J Bone Miner Res (2004) 1.26
Cathepsin and calpain inhibitor E64d attenuates matrix metalloproteinase-9 activity after focal cerebral ischemia in rats. Stroke (2006) 1.25
Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem (2004) 1.24
A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res (2015) 1.23
Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J Biol Chem (2005) 1.20
Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Sci (2008) 1.19
Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab (2005) 1.17
Pin1 down-regulates transforming growth factor-beta (TGF-beta) signaling by inducing degradation of Smad proteins. J Biol Chem (2009) 1.16
Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice. J Biol Chem (2002) 1.13
Transcriptional induction of FosB/DeltaFosB gene by mechanical stress in osteoblasts. J Biol Chem (2004) 1.12
Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One (2010) 1.11
A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone (2009) 1.09
Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment. Theranostics (2013) 1.07
A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome. J Biol Chem (2004) 1.07
HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunol Immunother (2008) 1.07
Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PLoS One (2011) 1.06
Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT. Bone (2011) 1.06
Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab (2014) 1.05
Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol (2004) 1.03
Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity. J Exp Med (2009) 1.01
Reference database of biochemical markers of bone turnover for the Japanese female population. Japanese Population-based Osteoporosis (JPOS) Study. Osteoporos Int (2004) 0.99
Androgen-androgen receptor system protects against angiotensin II-induced vascular remodeling. Endocrinology (2009) 0.98
Attenuation of brain damage and cognitive impairment by direct renin inhibition in mice with chronic cerebral hypoperfusion. Hypertension (2011) 0.97
Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res (2007) 0.97
Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models. Oncol Rep (2006) 0.97
TGF-β-related mechanisms of bone destruction in multiple myeloma. Bone (2010) 0.97
Complete genome sequence of Sphingobium sp. strain SYK-6, a degrader of lignin-derived biaryls and monoaryls. J Bacteriol (2012) 0.96
Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem (2002) 0.96
A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Res (2007) 0.96
Multiple myeloma complicated by autoimmune hemolytic anemia. Intern Med (2004) 0.95
Retracted Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acetyltransferase complex. Mol Cell Biol (2002) 0.95
Ultrasonic scalpel for gastric cancer surgery: a prospective randomized study. J Gastrointest Surg (2012) 0.94
Mechanical stress induces Interleukin-11 expression to stimulate osteoblast differentiation. Bone (2009) 0.94
Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. Int J Hematol (2007) 0.94
Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice. Mol Endocrinol (2010) 0.94